Study examines effectiveness of antiviral drug to treat mononucleosis


Study examines effectiveness of antiviral drug to treat mononucleosis
University of Minnesota researchers have begun studying a new drug to treat infectious mononucleosis, commonly known as mono. The goal of the study is to find out if people who take the antiviral drug valomaciclovir recover from mono faster.

This is the first clinical test of valomaciclovir for mono, and it is being conducted exclusively at the University of Minnesota.

"Mono has an enormous impact on young adults, especially on a college campus. Reducing the severity and length of the symptoms would mean less time away from school and work," said Henry Balfour, Jr., M.D., who heads the clinical trial. "Additionally, what we learn from studying mono in otherwise healthy people may have important implications for transplant or cancer patients, who are at risk for more severe illnesses caused by the same virus, called Epstein-Barr virus."

Epstein-Barr virus (EBV) is a member of the herpes virus family, and is transmitted mainly through saliva.

Anyone over the age of 18 whose mono symptoms are less than a week old may be eligible to join the study; the researchers hope to recruit 40 participants during 2008. The clinical trial is placebo-controlled, meaning participants will be randomly assigned to receive valomaciclovir or a look-alike pill that contains no medicine. This enables the researchers to determine scientifically whether or not the drug is effective.

Participants who qualify for the study will visit the research clinic 10 times over a six-month period. At each visit, the participant will have blood drawn and will gargle with a solution; both samples will help the researchers determine if the drug is working. Participants will be compensated at each visit with a gift card for the University of Minnesota Bookstore.

(Published at Health News Track on February 1, 2008 - 340 days ago)

Mononucleosis article/news source:

University of Minnesota - read other health news articles from University of Minnesota and health news articles from USA.

Mononucleosis - search related terms:

Antiviral, Cancer, Drug, Herpes, Medicine, Mono, Mononucleosis, Saliva, Transplant, Valomaciclovir, Virus,


»» Researchers discover a pathway to turn off immune system
«« Research suggests why scratching is so relieving


Mission
Health Newstrack is dedicated to serve recent and updated health news & medical research, events/news, views/reviews to its subscribers and free access to general public, health & medical professionals, and other health seekers worldwide online with a user-friendly system.
Bookmark this page
Health News Track is tracking world's medical health news daily.
Search :

Add to Google
Current news
University of Minnesota researchers have begun studying a new drug to treat infectious mononucleosis, commonly known as mono.
Mononucleosis
Infectious mononucleosis (IM), also called mono or glandular fever, is caused by the Epstein-Barr virus, is commonly transmitted among teenagers and young adults by kissing or sexual activity; hence it is sometimes called the "kissing disease." Mononucleosis in teenagers and young adults may result in acute symptoms that last for several weeks. Fatigue and low energy can linger for several months.

Mononucleosis articles
Add health news article to: Digg | Del.icio.us | Newsvine | Reddit | Fark | Yahoo | Technorati | RSS
The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.
We comply with the HONcode principles for trustworthy health information, verify here.
www.healthnewstrack.com - About us, Editorial team, Advertising, Jobs, Links, Privacy policy, Disclaimer, Feedback,
Site map, List health news, Health news organizations, Health news world, Accessibility, Glossary, Testimonials, Blog
Mobile/PDA Submit press release
© 2007-2008 HealthNewstrack.com
Track Health News Daily
1.51